Sarepta's Worst Week Just Rewrote the Gene Therapy Playbook

In 2026, things got tighter. Second-quarter total revenues of $401.3 million, with Elevidys contributing $98.1 million, missed Wall Street's expectations. Analysts pointed to the narrower label and physician hesitation as the culprits. Meanwhile, Sarepta was burning through cash and staring down 2027 financial obligations that demanded a reset.

The restructuring is designed to generate about $400 million in annual savings. That's not a trim; it's a tourniquet.

Why 500 People Lost Their Jobs

Layoffs at biotech companies are sadly common, but the scale here matters. Cutting 36% of your workforce signals something deeper than "operational efficiency." Sarepta paired the headcount reduction with a pipeline reprioritization, stopping or deprioritizing several gene therapy programs outside its core Duchenne focus.

The logic is straightforward, even if the human cost isn't: Elevidys is generating less revenue than planned, the addressable patient population just shrank because of the label change, and the company needs to extend its financial runway. When your flagship product takes a hit, you don't keep funding moonshots. You circle the wagons.

New monitoring requirements also add friction. Doctors must now order weekly liver function tests for at least three months after infusion, plus cardiac monitoring in the early post-infusion period. More monitoring means more logistical burden on treatment centers, which can slow the pace of new patient starts.

A Bigger Story for Gene Therapy

Sarepta's troubles don't exist in a vacuum. The FDA has been tightening the screws on gene therapy safety across the board in 2025 and 2026. Black box warnings hit other advanced therapies too, including CAR-T products like CARVYKTI for immune-related gut inflammation. The agency also restricted eli-cel (Skysona) after reviewing blood cancer risks.

The pattern is clear: accelerated approval is no longer a get-out-of-jail-free card. The FDA is willing to grant early access based on promising data, but it will come back and narrow the label if safety signals emerge post-launch. For companies building commercial plans around broad initial indications, that's a sobering reality check.

Analysts are split on what this means for Elevidys specifically. The optimists argue the black box warning was largely priced in, since non-ambulatory shipments had already been paused. The pessimists counter that physician and family confidence may be harder to rebuild, especially when the words "fatal liver failure" are printed in a black box on the label.

The Competitive Landscape Just Got Interesting

Sarepta's stumble opens the door for rivals. Solid Biosciences dosed its first patient in a Phase 3 trial (called IMPACT DUCHENNE) for its next-generation micro-dystrophin gene therapy, SGT-003, in May 2026. REGENXBIO is also pushing RGX-202 toward a potential regulatory filing. Meanwhile, Pfizer effectively exited the Duchenne gene therapy race in late 2024, scaling back its mini-dystrophin program.

The competitive dynamics have shifted from "can anyone catch Sarepta?" to "can Sarepta hold its lead while wounded?" If Solid or REGENXBIO can show cleaner safety profiles, the first-mover advantage that Elevidys once enjoyed could erode quickly. In rare disease, trust matters enormously; parents are making one-shot treatment decisions for their children.

What Happens Next

Sarepta isn't dead. Elevidys is still the only approved AAV gene therapy for Duchenne, and positive three-year Phase 3 data reported in January 2026 suggests the drug does work for the right patients. But "works for the right patients" is a much smaller story than "works for everyone with Duchenne."

The restructuring buys time. The $400 million in projected annual savings should help Sarepta meet its 2027 obligations and keep the lights on while it figures out a narrower, more sustainable commercial model. The question is whether investors, physicians, and families will stick around long enough for the company to prove that Elevidys still deserves a place in the Duchenne treatment landscape.

For the broader gene therapy field, the lesson is uncomfortable but important: getting a drug approved is just the beginning. Keeping it on the market, with a label that actually supports a viable business, is the harder part. Sarepta is learning that lesson in real time, and the rest of the industry is taking notes.

The ADHD Drug That Has Nothing to Do With Stimulants

Alkermes just dropped early data on ALKS 7290, a drug that treats ADHD through an entirely different brain system than any existing therapy. It's the first time an orexin agonist has shown clinical benefit in ADHD, and the implications for a $17+ billion market are hard to ignore.